Vireo Health Claims Largest Selection Of Cannabis Flower At Any New York Dispensary

2.6 min readPublished On: April 29th, 2021By
NEW YORK–Vireo Health (CSE: VREO; OTCQX: VREOF), a multi-state cannabis company, today announced the launch of the Company’s first line of ground medical cannabis flower in New York. The new line of ground flower will be expanded to four strains and is available at all four of the Company’s dispensaries in New York and via Home Delivery.
The ground flower line is sold in 3.5-gram and 7-gram jars and will be expanded to feature indica, sativa, and hybrid strains such as Killer Kush, Wedding Cake, and a Kosher-approved Tangie Kush. By September, Vireo expects to expand the ground flower line to include more than 20 different cannabis strains. Ground cannabis flower is now allowed by the New York Department of Health for medical cannabis patients to vaporize.

“Vireo is excited to launch a full line of medical cannabis flower products for our patients in New York,” said Chairman and Chief Executive Officer, Dr. Kyle Kingsley. “Allowing the sale of medical cannabis in its natural form – as dry flower – is the most effective way to reduce the cost of medical cannabis. By offering dry flower, we can increase patient accessibility, affordability, and greatly expand our product offerings. This will not only help existing medical cannabis patients but also make the program more attractive to all New Yorkers.”

With the launch of the Company’s ground flower products, Vireo will now carry ground flower from three state-registered growers at all four Vireo dispensaries, located in Queens, Albany, White Plains, and Binghamton, and through the Company’s Home Delivery service. This represents the largest selection of ground flower products at any New York dispensary.

“As a board-certified physician in New York, I believe that allowing dry flower into the medical cannabis program will help protect public health and safety by limiting the number of New Yorkers who purchase cannabis from illicit markets,” said Vireo Health Chief Medical Officer, Dr. Stephen Dahmer. “Patients who cannot afford the state’s program often seek out their medicine through these illicit markets. This unfortunate reality leads to vulnerable patients using unsafe and untested products without guidance or support. In the illicit market, there is no tracking of a product’s potency nor its potential contamination with pesticides, heavy metals, or other adulterants.”

Forward Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. Forward-looking information contained in this press release may be identified by the use of words such as “plans,” “will,” “expects,” or “believe”. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

(This information is primarily sourced from Vireo.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News